Welcome to our dedicated page for Perimeter Medical Imaging Ai news (Ticker: PYNKF), a resource for investors and traders seeking the latest updates and insights on Perimeter Medical Imaging Ai stock.
Overview
Perimeter Medical Imaging AI Inc is a commercial-stage medical technology company dedicated to transforming cancer surgery through ultra-high-resolution, real-time imaging solutions. The company specializes in advanced optical coherence tomography (OCT) and artificial intelligence (AI) systems, enabling surgical teams to visualize tissues at a cellular level during operations. Its FDA-cleared S-Series OCT system and the investigational B-Series OCT with ImgAssist AI represent a significant advancement in intraoperative imaging, directly addressing the challenge of accurately determining surgical margins and reducing re-excision rates.
Core Technologies and Applications
At the heart of Perimeter's offerings is its state-of-the-art OCT technology, which leverages light to capture detailed, cross-sectional images of excised tissues. This technology provides real-time visual feedback in the operating room, offering surgeons a powerful tool for margin assessment during procedures such as breast-conserving surgeries. By integrating proprietary AI algorithms through its ImgAssist system, Perimeter enhances the imaging process to detect residual cancer with greater precision compared to traditional methods like X-ray, ultrasound, or MRI.
The company’s clinical applications focus on:
- Surgical Margin Visualization: Enabling surgeons to identify regions of interest and determine the adequacy of surgical resection in real-time.
- Intraoperative Decision Support: Assisting with margin evaluation during procedures, potentially minimizing the likelihood of repeat surgeries.
- Advanced Imaging in Oncology: Meeting a critical need in cancer surgery by providing high-resolution images that enhance clinical outcomes.
Industry Context and Market Position
Operating within the highly competitive medical imaging and surgical technology industry, Perimeter Medical Imaging AI leverages its expertise in both hardware and software to offer breakthrough diagnostic tools. The integration of AI with real-time imaging distinguishes the company from traditional imaging providers by offering enhanced decision support in the surgical environment. This dual approach not only supports more precise surgical interventions but also underlines the company’s commitment to addressing significant unmet clinical needs.
Perimeter’s technology is designed to integrate seamlessly into existing surgical workflows. Its products have been showcased at international conferences and are supported by rigorous clinical trials, which are instrumental in cementing its reputation for clinical validation and technological innovation. The company’s advancements contribute to improved patient care by potentially improving surgical outcomes and reducing healthcare costs associated with reoperations.
Business Model and Operational Excellence
Perimeter Medical Imaging AI generates revenue from several streams including direct device sales, consumables, system leases, and potential licensing opportunities. The company’s strategic focus on clinical trials and surgeon education is central to driving market adoption. By collaborating with healthcare providers and leveraging grant funding to support clinical research, Perimeter aims to validate its technology and build a robust user base within key market segments.
The operational excellence of Perimeter is underscored by its ability to integrate clinical insights with advanced technological solutions. The company continuously develops and refines its products to meet the practical needs of the surgical community, ensuring that its imaging tools remain at the forefront of innovation in cancer surgery.
Commitment to Expertise, Experience, and Trust
Perimeter Medical Imaging AI upholds stringent standards of quality and clinical validation. This commitment is reflected in its extensive efforts in clinical trials, regulatory approvals, and the incorporation of feedback from leading surgical oncologists. The company’s leadership combines rich experience in the fields of medical technology and AI, lending credibility and depth to its innovations. Detailed clinical studies and rigorous testing protocols enhance the transparency and reliability of its imaging systems.
By fostering ongoing research and maintaining a proactive approach to technological development, Perimeter establishes itself as an authoritative source of innovation in intraoperative imaging. This approach not only demonstrates deep industry knowledge but also builds enduring trust among healthcare providers, investors, and other stakeholders.
Competitive Differentiation
Unlike traditional imaging methods, Perimeter’s solutions provide surgeons with immediate, actionable insights during operations. The company differentiates itself through a combination of high-resolution imaging and AI-driven interpretation, which together enhance the accuracy and efficiency of margin assessments. This differentiation is supported by:
- Robust clinical validation through pivotal trials.
- Strategic partnerships and active participation in international medical conferences.
- An extensive proprietary image data set that fuels continuous AI model improvement.
Conclusion
Perimeter Medical Imaging AI Inc is a pioneer in employing advanced OCT and AI technologies to redefine the standards of cancer surgery. Its innovative platforms support surgeons in making well-informed, real-time decisions that potentially reduce the risk of reoperations and improve overall patient outcomes. Through its commitment to deep clinical validation, technological rigor, and continuous innovation, Perimeter maintains its position as a significant and trustworthy contributor to the field of surgical imaging.
Perimeter Medical Imaging AI, Inc. (TSXV: PINK, OTC: PYNKF) announced its participation at the 24th Annual Meeting of the American Society of Breast Surgeons (ASBrS) from April 26-30, 2023, in Boston, MA. The company will host an educational symposium titled "ACT IN THE MOMENT: OCT adds real-time clarity on margin status," featuring prominent breast surgeons who will share their experiences utilizing the Perimeter S-Series Optical Coherence Tomography (OCT) technology. This device provides real-time imaging to assist surgeons during procedures. Perimeter will also offer live demonstrations at Booth #923, showcasing the OCT system's capabilities in visualizing tissue margins at a cellular level. The event underscores Perimeter's commitment to advancing breast cancer surgery technology.
Perimeter Medical Imaging AI, Inc. (OTC: PYNKF) announced the first commercial placement of its Perimeter S-Series OCT system in Utah on April 25, 2023. This FDA-cleared imaging tool, launched in 2021, enhances cancer surgery with real-time, cross-sectional visualization of excised tissues. Dr. Jennifer J. Tittensor, a breast surgeon, will utilize the system to improve margin assessments during surgeries. Perimeter's CEO, Jeremy Sobotta, noted growing interest from surgeons, indicating a positive sales momentum. The company is also advancing its next-generation Perimeter B-Series OCT with ImgAssist AI, supported by a grant of up to $7.4 million from the Cancer Prevention and Research Institute of Texas, highlighting its commitment to innovation in oncological surgery.
Perimeter Medical Imaging AI, Inc. (TSXV: PINK, OTC: PYNKF) announced its participation in the 2023 Bloom Burton & Co. Healthcare Investor Conference on April 25-26, 2023, in Toronto. The company, focused on revolutionizing cancer surgery through advanced imaging technologies, aims to address significant unmet medical needs.
Key details include:
- Company Presentation: April 26, 2023, from 11:00-11:30 AM ET.
- Webcast Link: Register here.
- Presenter: Jeremy Sobotta, CEO.
Perimeter aims to enhance surgical outcomes with its Perimeter S-Series OCT system and investigates the Perimeter B-Series OCT with cutting-edge AI technology, supported by a US$7.4 million grant for clinical trials.
Perimeter Medical Imaging AI, Inc. (TSXV: PINK, OTC: PYNKF) reported its financial results for the year ended December 31, 2022, revealing a net loss of $9.9 million, down from $13.3 million in 2021. Operating expenses rose to $16.6 million from $12.9 million, with cash used in operations at $11.9 million. The company successfully completed a private placement generating C$48.7 million and doubled its commercial installed base of the Perimeter S-Series OCT in Q4 2022. All eight clinical trial sites for the B-Series OCT system were activated, with expansion authorized. The company anticipates completion of patient enrollment in its trial by the end of 2023.
Additionally, the company aims to enhance the surgical outcomes during breast conservation surgery through its innovative imaging technology.
Perimeter Medical Imaging AI, Inc. (PYNKF) will announce its financial and operational results for the year ending December 31, 2022, on April 11, 2023, after U.S. market close. The company aims to transform cancer surgery through advanced imaging technology. The conference call is scheduled for the same day at 5 PM ET, featuring CEO Jeremy Sobotta. Investors can join via a dial-in number or a webcast. The Perimeter S-Series OCT system is FDA-cleared for real-time visualization of excised tissues, while the B-Series OCT is undergoing pivotal trials with funding support of up to $7.4 million from the Cancer Prevention and Research Institute of Texas.
Perimeter Medical Imaging AI has published a new white paper on the efficacy of its Perimeter S-Series OCT technology in breast conserving surgeries for ductal carcinoma in situ. The paper, authored by Dr. Amelia Tower, outlines three case studies where the technology enabled real-time margin visualization, allowing for intraoperative decisions that eliminated the need for additional surgeries. CEO Jeremy Sobotta highlighted the technology's potential to improve patient outcomes and reduce healthcare costs. The white paper was also presented at the SSO 2023 International Conference, showcasing Perimeter's commitment to advancing cancer surgery through innovative imaging tools.
Perimeter Medical Imaging AI, Inc. (TSXV: PINK, OTC: PYNKF) announced its participation in the Society of Surgical Oncology's International Conference on Surgical Cancer Care (SSO 2023) from March 22-25, 2023, in Boston, MA. The company will feature its S-Series OCT device during a spotlight presentation and demonstrations. This advanced imaging technology enhances margin assessment in real-time during surgeries, aiming to improve patient outcomes by reducing the need for repeat surgeries. Additionally, Perimeter engaged Red Cloud Securities for liquidity services to boost market stability and share liquidity, commencing March 15, 2023.
Perimeter Medical Imaging AI, a commercial-stage medical technology company, announced its AI technology is featured in the "Artificial Intelligence: Your Mind & The Machine" exhibit at the Museum of Science & History (MoSH) in Memphis, TN, running until May 6, 2023. The company’s CEO, Jeremy Sobotta, emphasized the significance of their next-gen ultra-high resolution optical imaging technology being evaluated in clinical trials at the West Cancer Center. Supported by AI industry leaders, Perimeter aims to enhance surgical decision-making for cancer patients. The company’s innovative imaging systems are FDA-cleared and are backed by a grant of up to $7.4 million from the Cancer Prevention and Research Institute of Texas.
Perimeter Medical Imaging AI (PYNKF) announced significant leadership changes, appointing Suzanne Foster as the new Chair of the Board of Directors. Effective immediately, her extensive background in healthcare will enhance the company's mission in cancer surgery technology. CEO Jeremy Sobotta expressed confidence in Foster's leadership, praising her experience within the organization. Former Chair Dr. Anthony Holler remains as a director. Additionally, Chris Scott resigned as CFO, with Russell Wagner stepping in as Interim CFO while a search for Scott’s replacement begins. Perimeter aims to leverage its advanced imaging technology to improve patient outcomes.
Perimeter Medical Imaging AI (TSX-V: PINK, OTC: PYNKF) announced the completion of two additional installations of its S-Series OCT system at the end of 2022, successfully doubling its commercial installed base during Q4. CEO Jeremy Sobotta emphasized the momentum in their business, particularly within a major healthcare system, enhancing the value perceived by early users. This expansion aims to improve patient outcomes and reduce healthcare costs in the U.S.
FAQ
What is the current stock price of Perimeter Medical Imaging Ai (PYNKF)?
What is the market cap of Perimeter Medical Imaging Ai (PYNKF)?
What does Perimeter Medical Imaging AI Inc specialize in?
What are the core products offered by the company?
How does the company improve surgical outcomes?
What role does artificial intelligence play in their technology?
In which market segments does Perimeter operate?
How does the company support clinical validation for its products?
What differentiates Perimeter's technology from traditional imaging methods?
How does Perimeter generate revenue?
Where is Perimeter Medical Imaging AI Inc headquartered?
